Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PTGES | O14684 | 6/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.37 |
| ▸ | CETP | P11597 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473321 | 0.90 | MEN1 (0.40) | KMT2ALMNACTSLCTSSSMN1; SMN2 | |
| SCHEMBL6463649 | 0.90 | MEN1 (0.40) | KMT2ALMNACTSLCTSSSMN1; SMN2 | |
| SCHEMBL6466336 | 0.89 | MEN1 (0.40) | KMT2ALMNACTSLCTSSSMN1; SMN2 | |
| SCHEMBL7186564 | 0.89 | MMP1 (0.39) | KMT2ACTSLCTSSPTGESMEN1 | |
| SCHEMBL7042906 | 0.87 | DAGLA (0.46) | KMT2ALMNASMN1; SMN2MEN1RAB9A | |
| SCHEMBL6465251 | 0.85 | LMNA (0.40) | KMT2ALMNACTSLCTSSTP53 | |
| SCHEMBL7045308 | 0.83 | CTSS (0.49) | KMT2ALMNACTSLCTSSTP53 | |
| SCHEMBL7047598 | 0.83 | CTSL (0.40) | KMT2ALMNACTSLCTSSTP53 | |
| SCHEMBL7723017 | 0.78 | LMNA (0.45) | KMT2ALMNACTSLTP53SMN1; SMN2 | |
| SCHEMBL6473243 | 0.78 | BMP1 (0.41) | KMT2ACTSLCTSSSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | KMT2A 3705/4885LMNA 1755/4885CTSL 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.